{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ixazomib+citrate&page=2", "query": { "intervention": "ixazomib citrate", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 113, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ixazomib+citrate&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ixazomib+citrate&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T22:58:21.607Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02481310", "title": "Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Burkitt Lymphoma", "B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma", "Diffuse Large B-Cell Lymphoma", "MYC Gene Mutation", "Plasmablastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2015-10-28", "completion_date": "2024-07", "has_results": true, "last_update_posted_date": "2022-02-21", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 5, "location_summary": "Chicago, Illinois • Medford, Massachusetts • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Medford", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02481310" }, { "nct_id": "NCT02633059", "title": "Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Loss of Chromosome 17p", "Recurrent Plasma Cell Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Idasanutlin", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2015-12-30", "completion_date": "2022-11-01", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 8, "location_summary": "Duarte, California • Jacksonville, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02633059" }, { "nct_id": "NCT04847453", "title": "Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent AL Amyloidosis", "Refractory AL Amyloidosis" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Transabdominal Ultrasound", "type": "PROCEDURE" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-08-03", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 16, "location_summary": "Duarte, California • Sacramento, California • Atlanta, Georgia + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04847453" }, { "nct_id": "NCT02302846", "title": "Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-03-20", "completion_date": "2017-05-30", "has_results": true, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02302846" }, { "nct_id": "NCT02831686", "title": "A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Relapsed and/or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2016-07", "completion_date": "2020-11-19", "has_results": false, "last_update_posted_date": "2020-11-24", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02831686" }, { "nct_id": "NCT00830869", "title": "A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Non-hematologic Malignancies" ], "interventions": [ { "name": "IXAZOMIB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2009-03-02", "completion_date": "2012-04-20", "has_results": true, "last_update_posted_date": "2019-09-09", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 6, "location_summary": "Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00830869" }, { "nct_id": "NCT03770260", "title": "Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2020-02-10", "completion_date": "2023-07-06", "has_results": true, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Tampa, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03770260" }, { "nct_id": "NCT02921893", "title": "Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Plasmacytoma", "POEMS Syndrome" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2016-10-31", "completion_date": "2024-05-13", "has_results": false, "last_update_posted_date": "2025-02-12", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02921893" }, { "nct_id": "NCT02384746", "title": "Phase I Study of the Combination of MLN9708 and Fulvestrant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "MLN9708", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2015-06-02", "completion_date": "2018-06-10", "has_results": false, "last_update_posted_date": "2019-04-29", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02384746" }, { "nct_id": "NCT02343042", "title": "Selinexor and Backbone Treatments of Multiple Myeloma Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Belantamab Mafodotin", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2015-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-01T22:58:21.607Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02343042" } ] }